Literature DB >> 28289350

The CHARM Trial of Adalimumab in Crohn's Disease.

Jean-Frédéric Colombel1.   

Abstract

Entities:  

Year:  2006        PMID： 28289350      PMCID： PMC5345212     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  3 in total

Review 1.  Emerging biological treatments in inflammatory bowel diseases.

Authors:  Gert Van Assche; Séverine Vermeire; Paul Rutgeerts
Journal:  Dig Dis       Date:  2006       Impact factor: 2.404

Review 2.  Autoimmunity and anti-TNF-alpha agents.

Authors:  Fabiola Atzeni; Maurizio Turiel; Franco Capsoni; Andrea Doria; Pierluigi Meroni; Piercarlo Sarzi-Puttini
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

3.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682
  3 in total
  2 in total

1.  Heterogeneity in pharmacological treatment and outcomes in Crohn's disease patients in Catalonia: a population-based observational study.

Authors:  Eduard Brunet; Emili Vela; Luigi Melcarne; Laura-Patricia Llovet; Anna Puy; Montserrat Clèries; Caridad Pontes; Pilar García-Iglesias; Albert Villòria; Gilaad G Kaplan; Xavier Calvet
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

2.  Adalimumab for maintenance of remission in Crohn's disease.

Authors:  Cassandra M Townsend; Tran M Nguyen; Jeremy Cepek; Mohamad Abbass; Claire E Parker; John K MacDonald; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Cochrane Database Syst Rev       Date:  2020-05-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.